Bancc.org

Summary table of consultee and commentator comments on review
proposal
Respondent
Response
proposal
Technology
Appraisal
any evidence to suggest that the Technology Appraisal Guidance No 47 itself should be reviewed. for patients with STEMI and this indication has recently been assessed by the Institute as part of the clinical guidelines on MI secondary prevention; and National Institute for Health and Clinical Excellence Letter notifying decision on review proposal for existing guidance Nos. 47 glycoprotein iib/iiia inhibitors in the treatment of acute coronary syndromes & 80 clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Issue Date: October 2007 Page 1 of 3 If you have any queries regarding this correspondence please contact Andrew Gyton by email: [email protected] or telephone: 020 7067 5886 interventions, including Glycoprotein IIb/IIIa inhibitors. An electronic copy of the ESC guidelines is attached and we would urge the GDG to take these into consideration when finalising the scope for the guideline and developing the guideline itself. sure that the institute will consider both ST elevation and non ST elevation Acute Coronary Syndromes in the clinical guideline as clinical evidence is increasing to support the use of Clopidogrel in the former as well as the latter. This will obviously also have to link with the Institute's recent consultation regarding Drug Eluting Stents and the recently released secondary prevention guidance post myocardial infarction. that associated with non-ST segment elevation myocardial infarction (NSTEMI) and ST- elevation myocardial infarction (STEMI). both safety and efficacy aspects of therapy. National Institute for Health and Clinical Excellence Letter notifying decision on review proposal for existing guidance Nos. 47 glycoprotein iib/iiia inhibitors in the treatment of acute coronary syndromes & 80 clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Issue Date: October 2007 Page 2 of 3 If you have any queries regarding this correspondence please contact Andrew Gyton by email: [email protected] or telephone: 020 7067 5886 for eptifibatide are explicitly incorporated into these guidelines. sensible to update these pieces of guidance within the context of a clinical guideline i.e. the NICE Clinical guideline on Acute Coronary Syndromes, as this is when these particular therapies are used mostly. We are aware that there have been numerous publications over the past couple of years, particularly on the use of Clopidogrel, although many of these are small studies. There is also a lot of variation in the use of Clopidogrel, so, we consider that an updated guidance document in some format from NICE is needed.
No response received from:
 Action Heart
National Institute for Health and Clinical Excellence Letter notifying decision on review proposal for existing guidance Nos. 47 glycoprotein iib/iiia inhibitors in the treatment of acute coronary syndromes & 80 clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Issue Date: October 2007 Page 3 of 3 If you have any queries regarding this correspondence please contact Andrew Gyton by email: [email protected] or telephone: 020 7067 5886 National Institute for Health and Clinical Excellence Letter notifying decision on review proposal for existing guidance Nos. 47 glycoprotein iib/iiia inhibitors in the treatment of acute coronary syndromes & 80 clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Issue Date: October 2007 Page 4 of 3 If you have any queries regarding this correspondence please contact Andrew Gyton by email: [email protected] or telephone: 020 7067 5886

Source: http://www.bancc.org/resources/76E_Appendix_A_-_comments_table.pdf